• E-mail :[email]
  • Phone : +33469856072
  • Location : Lyon, France
Last update 2020-02-10 14:45:59.845

Peter Mulligan Ph.D. Molecular Biology, University of London, 2003; H.D.R, University of Lyon, 2016; B.Sc., National University of Ireland, Galway, 1999.

Course and current status

Current position: Team Leader, Epigenetics and Cancer Team 

Cancer Research Center of Lyon (CRCL)


Scientific Career

2014      Inserm tenured researcher (CR1) since 10/2014

11/2013            Recruited as Team Leader by Cancer Research Center of Lyon (CRCL)

2008 – 2013 : Postdoc in epigenetics: Massachusetts General Hospital Cancer Center. Supervisor : Pr. Anders Naar

2003 – 2008 : Postdoc in epigenetics: Harvard Medical School, Boston, USA. Supervisor : Pr. Yang Shi


Scientific summary

Epigenetic alterations are fundamental to the development of virtually all cancers, promoting transcriptional changes that drive oncogenesis and malignant progression.

Unlike gene mutations, epigenetic perturbations can be reversed by small-molecule drugs. However, to date, only a handful of the dozens of epigenetic factors have entered the clinical and pre-clinical arena as drug targets.

We identify and validate novel epigenetic drug targets for cancer, using a combination of data-mining, bioinformatics, and proven wet-lab methodologies (biochemistry, molecular and cell biology, murine studies... ).

So far, this has led us to identify a novel candidate drug target, for which a patent application was submitted and a manuscript is under review. 

In addition we actively participate in several collaborations, assisting other researchers to investigate epigenetics-based approaches for cancer treatment.

Image d’exemple